Cargando…

Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Han Gyul, Oh, Dongryul, Ahn, Yong Chan, Noh, Jae Myoung, Pyo, Hongryull, Cho, Won Kyung, Song, Yun Mi, Park, Minsu, Hwang, Na Young, Sun, Jong-Mu, Kim, Hong Kwan, Zo, Jae Ill, Shim, Young Mog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226603/
https://www.ncbi.nlm.nih.gov/pubmed/32290037
http://dx.doi.org/10.3390/cancers12040925
_version_ 1783534327431168000
author Yoon, Han Gyul
Oh, Dongryul
Ahn, Yong Chan
Noh, Jae Myoung
Pyo, Hongryull
Cho, Won Kyung
Song, Yun Mi
Park, Minsu
Hwang, Na Young
Sun, Jong-Mu
Kim, Hong Kwan
Zo, Jae Ill
Shim, Young Mog
author_facet Yoon, Han Gyul
Oh, Dongryul
Ahn, Yong Chan
Noh, Jae Myoung
Pyo, Hongryull
Cho, Won Kyung
Song, Yun Mi
Park, Minsu
Hwang, Na Young
Sun, Jong-Mu
Kim, Hong Kwan
Zo, Jae Ill
Shim, Young Mog
author_sort Yoon, Han Gyul
collection PubMed
description Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients. Methods: We retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm(2)/m(2), and excessive muscle loss was defined as SMI change <−10.0%/50 days during NACRT. Moreover, laboratory test results, such as albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) before and after NACRT, were collected. Results: In the univariable Cox analysis, pre- (p = 0.689) and post-radiotherapy (RT) sarcopenia (p = 0.669) were not associated with OS. However, excessive muscle loss had a significant association with OS in both the univariable and multivariable analyses (all p = 0.001). Excessive muscle loss was also related to RFS in both the univariable (p = 0.011) and multivariable (p = 0.022) Cox analysis. Patients with excessive muscle loss had significantly lower levels of post-RT albumin (p < 0.001) and PNI (p < 0.001), higher levels of post-RT NLR (p = 0.031) and PLR (p = 0.071), larger decrease in albumin (p < 0.001) and PNI (p < 0.001) after NACRT, and larger increase in NLR (p = 0.051) and PLR (p = 0.088) after NACRT than in those with non-excessive muscle loss. Conclusion: Excessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers.
format Online
Article
Text
id pubmed-7226603
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72266032020-05-18 Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer Yoon, Han Gyul Oh, Dongryul Ahn, Yong Chan Noh, Jae Myoung Pyo, Hongryull Cho, Won Kyung Song, Yun Mi Park, Minsu Hwang, Na Young Sun, Jong-Mu Kim, Hong Kwan Zo, Jae Ill Shim, Young Mog Cancers (Basel) Article Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients. Methods: We retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm(2)/m(2), and excessive muscle loss was defined as SMI change <−10.0%/50 days during NACRT. Moreover, laboratory test results, such as albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) before and after NACRT, were collected. Results: In the univariable Cox analysis, pre- (p = 0.689) and post-radiotherapy (RT) sarcopenia (p = 0.669) were not associated with OS. However, excessive muscle loss had a significant association with OS in both the univariable and multivariable analyses (all p = 0.001). Excessive muscle loss was also related to RFS in both the univariable (p = 0.011) and multivariable (p = 0.022) Cox analysis. Patients with excessive muscle loss had significantly lower levels of post-RT albumin (p < 0.001) and PNI (p < 0.001), higher levels of post-RT NLR (p = 0.031) and PLR (p = 0.071), larger decrease in albumin (p < 0.001) and PNI (p < 0.001) after NACRT, and larger increase in NLR (p = 0.051) and PLR (p = 0.088) after NACRT than in those with non-excessive muscle loss. Conclusion: Excessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers. MDPI 2020-04-10 /pmc/articles/PMC7226603/ /pubmed/32290037 http://dx.doi.org/10.3390/cancers12040925 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yoon, Han Gyul
Oh, Dongryul
Ahn, Yong Chan
Noh, Jae Myoung
Pyo, Hongryull
Cho, Won Kyung
Song, Yun Mi
Park, Minsu
Hwang, Na Young
Sun, Jong-Mu
Kim, Hong Kwan
Zo, Jae Ill
Shim, Young Mog
Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_full Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_fullStr Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_full_unstemmed Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_short Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer
title_sort prognostic impact of sarcopenia and skeletal muscle loss during neoadjuvant chemoradiotherapy in esophageal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226603/
https://www.ncbi.nlm.nih.gov/pubmed/32290037
http://dx.doi.org/10.3390/cancers12040925
work_keys_str_mv AT yoonhangyul prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT ohdongryul prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT ahnyongchan prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT nohjaemyoung prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT pyohongryull prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT chowonkyung prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT songyunmi prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT parkminsu prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT hwangnayoung prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT sunjongmu prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT kimhongkwan prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT zojaeill prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer
AT shimyoungmog prognosticimpactofsarcopeniaandskeletalmusclelossduringneoadjuvantchemoradiotherapyinesophagealcancer